1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24250
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorLinardou, H.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorBamias, A.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorTimotheadou, E.en
dc.contributor.authorMakatsoris, T.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorDimopoulos, A. M.en
dc.date.accessioned2015-11-24T19:39:29Z-
dc.date.available2015-11-24T19:39:29Z-
dc.identifier.issn1741-7015-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24250-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCarboplatin/administration & dosage/adverse effectsen
dc.subjectDoxorubicin/administration & dosage/adverse effects/analogs & derivativesen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectKaplan-Meier Estimateen
dc.subjectMiddle Ageden
dc.subjectOvarian Neoplasms/diagnosis/*drug therapyen
dc.subjectPaclitaxel/administration & dosage/adverse effectsen
dc.subjectPolyethylene Glycols/administration & dosage/adverse effectsen
dc.subjectPrognosisen
dc.subjectProportional Hazards Modelsen
dc.subjectTreatment Outcomeen
dc.titleA randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1186/1741-7015-8-3-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20055981-
heal.identifier.secondaryhttp://www.biomedcentral.com/1741-7015/8/3-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2010-
heal.abstractBACKGROUND: Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting. METHODS: Patients with histologically confirmed recurrent OC, at the time of or more than 6 months after platinum-based chemotherapy, were randomized to six cycles of CP (carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21) or CLD (carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28). RESULTS: A total of 189 eligible patients (CP 96, CLD 93), with a median age of 63 years, median Performance Status (PS) 0 and a median platinum free interval (PFI) of 16.5 months, entered the study. Discontinuation due to toxicity was higher in the CP patients (13.5% versus 3%, P = 0.016). The overall response rate was similar: CP 58% versus CLD 51%, P = 0.309 (Complete Response; CR 34% versus 23%) and there was no statistical difference in time-to-progression (TTP) or overall survival (OS; TTP 10.8 months CP versus 11.8 CLD, P = 0.904; OS 29.4 months CP versus 24.7 CLD, P = 0.454). No toxic deaths were recorded. Neutropenia was the most commonly seen severe toxicity (CP 30% versus CLD 35%). More frequent in CLD were severe thrombocytopenia (11% versus 2%, P = 0.016), skin toxicity and Palmar-plantar erythrodysesthesia (PPE) grade 1-2 (38% versus 9%, P< 0.001), while grade 3 neurotoxicity and alopecia were higher in CP (7% versus 0%, P = 0.029, 20% versus 5%, P = 0.003). PS and PFI were independent prognostic factors for TTP and OS. CONCLUSIONS: The combination of pegylated LD with carboplatin is effective, showing less neurotoxicity and alopecia than paclitaxel-carboplatin. It thus warrants a further phase III evaluation as an alternative treatment option for platinum-sensitive OC patients. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry: ACTRN12609000436279.en
heal.journalNameBMC Meden
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Briasoulis-2010-a randomized phase.pdf332.03 kBAdobe PDFView/Open
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons